Blocking the EGFR pathway is linked to an increase in PD-L1 levels in tumor cells, leading to improved outcomes from PD-1/PD-L1 blockade therapy in cancers such as breast cancer and NSCLC [27, 142]. The gene discussed is CD274; the disease is breast carcinoma.